AZD2624 Multiple Ascending Dose Study in Japan (JMAD)

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy; Safety

Treatments: Drug: Placebo; Drug: AZD2624

Study type: Interventional

Funder types: Industry

Identifiers

NCT00696865

D0970C00006

Details and patient eligibility

About

This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624

Enrollment: 30 estimated patients

Sex: Male

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy young male Japanese volunteers

Exclusion criteria

• Significant illness, as judged by the investigator, within 2 weeks of screening visit or Day 1
• Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit or Day 1
• Blood loss in excess of 200 mL within 30 days of screening visit or Day 1, in excess of 400 mL within 90 days of screening visit or Day 1, or in excess of 1200 mL within 1 year of screening visit or Day 1
• Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator at screening or pre first dose

Trial design

30 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD2624

2

Placebo Comparator group

Treatment:

Drug: Placebo